Abstract 3900: Tegavivint, a first-in-class TBL1 inhibitor demonstrates potent activity in WNT-driven colorectal cancers.Raffaella Soldi, Sunil Sharma, Julissa Simmons et al.|Cancer Research|2026Cited by 0